SCHEMBL4252275

SCHEMBL4252275

CCN1CCN(CCCC(=O)c2ccc(OC)c(OC)c2OC)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 3/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2D6 P10635 1/20 0.46
ADRA2C P18825 1/20 0.46
OPRK1 P41145 1/20 0.46
KCNH2 Q12809 1/20 0.46
EBP Q15125 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
HTR4 Q13639 3/20 0.46
POLB P06746 1/20 0.45
KDM4E B2RXH2 3/20 0.44
ACHE P22303 2/20 0.44
SLC29A1 Q99808 1/20 0.43
THRB P10828 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11680015 0.86 OPRK1 (0.52) ALDH1A1LMNAHTR1AADRA2ACYP2D6
SCHEMBL4283460 0.79 ALDH1A1 (0.58) ALDH1A1GAALMNAPOLBKDM4E
SCHEMBL4251279 0.78 ALDH1A1 (0.40) ALDH1A1POLBKDM4EACHETHRB
SCHEMBL7212540 0.77 SETD7 (0.52) ALDH1A1LMNAHTR1AADRA2ACYP2D6
SCHEMBL4128743 0.77 PDE4B (0.51) ALDH1A1LMNAPOLBPDE4D
SCHEMBL4126956 0.76 PDE4D (0.50) LMNAPOLBPDE4D
SCHEMBL4120097 0.76 PDE4D (0.50) ALDH1A1LMNAMEN1KMT2APDE4D
SCHEMBL4255074 0.76 PDE4D (0.53) ALDH1A1LMNAMEN1KMT2APDE4D
SCHEMBL10541414 0.75 KMT2A (0.56) ALDH1A1LMNAHTR1AADRA2ACYP2D6
SCHEMBL10540938 0.75 KMT2A (0.50) ALDH1A1HTR1AADRA2ACYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176802-A1 ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS PAPADOPOULOS VASSILIOS 2009-07-09 US disclosed
US-20060247248-A1 Sigma-1 receptor ligand with acetylcholinesterase SAMARITAN PHARMACEUTICALS, INC. 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247248-A1 Sigma-1 receptor ligand with acetylcholinesterase SIGMAR1, CHRNE, ACHE ALDH1A1 691/4885GAA 1683/4885LMNA 2903/4885
US-20090176802-A1 ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS INA, ACHE, NLN ALDH1A1 1194/4885GAA 355/4885LMNA 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.